Tailored treatment available to patients with HER2-positive metastatic breast cancer based on the presence of active central nervous system disease.
Patients with HER2-positive metastatic breast cancer can now have treatment tailored based on the presence of active central nervous system (CNS) disease, due to substantial advances made in the past few years into small molecule inhibitors and macromolecule biologics, according to a presentation by Mark Pegram, MD, at the 39th Annual Miami Breast Cancer Conference®.1
“Macromolecule biologics, such as monoclonal antibodies or antibody-drug conjugates [ADCs], can penetrate the blood–brain barrier, resulting in objective responses,” Pegram, an associate dean for Clinical Research Quality, Stanford University School of Medicine, said during his lecture. “Tucatinib [Tukysa]-based therapy improves overall survival [OS] for patients with HER2-positive breast cancer with brain metastases, while maintaining overall health-related quality of life, with some potential benefit also seen in leptomeningeal metastasis.”
According to Pegram, several risk factors are associated with brain metastasis. These include triple-negative histology, high histological grade, increased Ki-67, nodal involvement, number of metastatic sites, short time to distant relapse, a tumor size smaller than 2 cm, and young age.
Another risk factor includes HER2 gene amplification/overexpression. There is an approximate 4-time greater risk of CNS disease in HER2-positive disease with brain metastasis appearing in approximately 50% of patients with HER2-positive metastatic disease, as noted by Pegram. Within the HER2 subtype, the SystHERs study of 977 patients further identified an age of less than 50 years, recurrent metastatic breast cancer, and hormone receptor negative status as additional risk factors for CNS metastases.2
While local therapy is commonly used to treat patients with brain metastases, it is associated with adverse events, according to Pegram. A reduction in the adverse events associated with local therapy was seen with stereotactic radiosurgery (SRS), which avoids the hippocampus, when compared with whole brain radiotherapy (WBRT), according to data from a phase 3 study of patients with 1 resected brain metastasis and a resection cavity less than 5 cm.3 These findings show grade 3 or higher cognitive disturbances reported in 3% of patients with SRS compared with 5% for WBRT, hearing impairment in 3% vs 9%, and grade 1/2 events were 16% and 23%, respectively.
“Brain metastases often occur quickly during the course of HER2-positive metastatic breast cancer, and negatively impacts quality of life and OS,” Pegram said. “Local therapy, while effective, does not prevent recurrence and can cause significant toxicities.”
Systemic Therapies for Brain Metastases
While the blood-brain barrier has been a key obstacle to developing effective systemic therapies to treat CNS disease, newer agents have shown signs of overcoming this challenge. Studies with 89zirconium-trastuzumab (89Zr-trastuzumab) have shown the ability of monoclonal antibodies to cross the blood-brain barrier. These studies use a high-dose version of trastuzumab (Herceptin) tested in combination with pertuzumab (Perjeta) for patients with HER2-positive metastatic breast cancer with progressive brain metastases. Promising results were demonstrated in the phase 2 PATRICIA study (NCT02536339).4 Here, the CNS objective rate (ORR) was 11% (95% CI, 3%-25%) and the median duration of response was 4.6 months; the 4- and 6-month clinical benefit rates were 68% and 51%, respectively.
Additionally, the HER2-targeted ADC ado-trastuzumab emtansine (T-DM1; Kadcyla) has shown efficacy in patients with brain metastases and HER2-positive metastatic breast cancer.5 ORRs in this retrospective study were similar between those with brain metastases (35.1%) and in those without (38.3%), demonstrating the efficacy of ADCs in this space. Disease control rates were 53.3% and 66.6%, and the median OS was 14.0 months (95% CI, 12.2-15.8) in the patients with brain metastases compared with 32.0 months (95% CI, 24.4-39.6) in those without (P < .0001).
The ability of ADCs to cross the blood-brain barrier to elicit intracranial responses was further demonstrated with fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in the phase 3 DESTINY-Breast03 study (NCT03529110), with intriguing efficacy noted in patients with brain metastases that was superior for T-DXd over T-DM1.6 Data from this study revealed the intracranial response rate to be 63.9% with T-DXd compared with 33.3% for T-DM1. Ultimately, T-DXd remained superior to T-DM1 across several efficacy end points in addition to response for patients with brain metastases.
The small molecule inhibitor tucatinib, in combination with trastuzumab and capecitabine, has also demonstrated efficacy for patients with brain metastases in the HER2CLIMB study (NCT02614794). The confirmed intracranial ORR with tucatinib was 47.3% compared with 20.0% with placebo, trastuzumab, and capecitabine.7 In updated results, this also translated to a marked improvement in progression-free survival and OS.8
Results from HER2CLIMB led the FDA to approve tucatinib in April 2020 for use in combination with trastuzumab and capecitabine, for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. This includes those with brain metastases, who have received 1 or more prior anti–HER2-based regimens in the metastatic setting.9
This tucatinib regimen also was examined as a potential treatment for patients with HER2-positive breast cancer and leptomeningeal metastasis, in the phase 2 TBCRC049 study.10 Data from this study showed 35% of patients to remain alive at a median follow-up of 18 months. Median OS was 10 months (95% CI, 4.1-not reached) and median time to CNS progression was 6.9 months (95% CI, 2.3-13.8).
“Following taxane, trastuzumab, and pertuzumab therapy, T-DXd is now the preferred regimen for those without CNS disease. For those with active CNS disease, clearly tucatinib, trastuzumab, and capecitabine is a strong consideration, because there's level 1 evidence of OS benefit with statistical confidence,” Pegram said. “For those with stable CNS disease, it is probably more of a toss-up.”
Now that there are a number of agents available with proven efficacy in brain metastases, Pegram noted that screening guidelines should be updated to look for CNS involvement more frequently. “Screening guidelines recommend screening for CNS metastases only in symptomatic patients, but this may not adequately capture all patients with brain metastases,” he concluded.